ABSTRACT
The processes of developed in CNS the complicated stroke and developments of fittings for their pharmaceutical therapy were developed and offering by standardized method of the experimental secondary stroke in rats, suitable for the use in sharp and chronic researches. Variant of repeated hemorrhagic stroke consist of autohemorrhagic right hemisphere stroke by the mechanical damage of brain tissue after 10-daily occlusion of right common carotid artery was studied. A model is comfortable for reproducing of the repeated standardized local damage of brain, is more adequate form of design of transient and chronic cerebrovascular pathology, than the independent use of local hemorrhage of autoblood in the brain of animals. The morphological description of model approaches the clinical variants of development and flow of sharp hemorrhagic stroke after a previous chronic cerebral insufficiency on an ischemic type.
Subject(s)
Cerebral Hemorrhage/etiology , Cerebral Infarction/etiology , Animals , Brain/pathology , Carotid Artery Injuries/complications , Disease Models, Animal , Female , RatsABSTRACT
The mechanism of therapeutic action of cortical neurotropic factors (CNTF) was studied in hemorrhagic stroke. In intracerebral hemorrhage, CNTFs were shown to elevate the level of nerve growth factor mRNA and at the same time, produce no effect on its level in intact animals. The neuroactivating action of CNTF in the acute phase of hemorrhagic stroke was achieved by intranasal administration due to the retrograde axon transport of CNTF molecules along the olfactory nerve fibers to the brain, by passing the blood-brain barrier. It was ascertained that the molecules of tritium-labeled CHTF accumulated in the central nervous system following 20 minutes and the level of label accumulation is proportionally increased after 120 minutes. The pattern of accumulation of the intranasally administered label in the olfactory tract and olfactory bulb proves CNTF transportation along these structures of the nervous system. Therefore, when intranasally administered, CNTFs are able to transport to the central nervous system along the olfactory tract and to enhance the expression of nerve growth factor mRNA in hemorrhagic stroke.
Subject(s)
Blood-Brain Barrier/metabolism , Cerebral Hemorrhage/metabolism , Cytokines/biosynthesis , Gene Expression Regulation , Nerve Growth Factors/biosynthesis , Nerve Growth Factors/pharmacology , Stroke/metabolism , Acute Disease , Animals , Male , RatsABSTRACT
Hemorrhagic stroke (intracerebral hemorrhage) is a socially significant cerebrovascular disease. Despite high mortality and disability rates, hemorrhagic stroke has been experimentally studied to a lesser extent than ischemic stroke. The modeling of hemorrhagic stroke may be used to solve a number of fundamental and practical problems. The present review deals with the review of the currently available procedures for modeling hemorrhagic stroke.
Subject(s)
Cerebral Hemorrhage , Disease Models, Animal , Stroke , Animals , HumansABSTRACT
Effects of the nootropic neuropeptide drugs cerebrolysin (Ebewe, Austria) and cortexin (Geterofarm, Russia) on the immunocompetent cells (T-lymphocytes of the MT-4 cell line and B-lymphocytes of the Raji cell line) were studied in vitro. The cell viability was evaluated using the MTT test by counting living and dead cells upon incubation under various conditions with a vital stain (Trypan Blue). It is established that cerebrolysin exhibits cytoprotective properties with respect to both T- and B-lymphocytes and favors the survival of immunocompetent cells. In addition, cerebrolysin in certain concentrations produces a proliferative effect on B-lymphocytes, thus stimulating the formation of immune memory B cells. In contrast, cortexin in certain concentrations produces a cytotoxic and antiproliferative action on T-lymphocytes. The parameters of influence for both drugs depend on their concentration in the cell incubation medium, the duration of action, and (most significantly) the cell type. These properties may account for one of the possible mechanisms of the immunoprotective action of cerebrolysin in various neurological states accompanied by immune response disorders.
Subject(s)
Amino Acids/pharmacology , B-Lymphocytes/immunology , Cell Proliferation/drug effects , Lymphocyte Activation/drug effects , Nootropic Agents/pharmacology , Peptides/pharmacology , Amino Acids/immunology , Animals , Cell Line, Tumor , Cell Survival/drug effects , Cell Survival/immunology , Cytoprotection/drug effects , Cytoprotection/immunology , Dose-Response Relationship, Drug , Humans , Immunologic Memory/drug effects , Immunologic Memory/immunology , Intercellular Signaling Peptides and Proteins , Lymphocyte Activation/immunology , Mice , Nootropic Agents/immunology , Peptides/immunology , T-LymphocytesABSTRACT
The purpose of the investigation was to study whether latent virus infection may activate in the murine brain using a model of hemorrhagic stroke. Acute intracerebral hemorrhagic stroke was induced in the internal capsule in accordance with the original technology. For experimental reproduction of virus meningoencephalitis, albino mice were infected with a sublethal dose of herpes simplex virus. The investigation ascertained persistent virus activation, as shown by the polymerase chain reaction technique that detected herpes simplex virus type 1 in the blood and brain of the animals, as well as the development of a cerebral inflammatory lesion associated with acute hemorrhagic stroke. The findings suggest that encephalitis may develop in acute stroke due to herpes simplex virus reactivation from the latent state, which will improve monitoring and treatment quality in acute stroke.
Subject(s)
Encephalitis, Viral/etiology , Herpesvirus 1, Human/physiology , Intracranial Hemorrhages/complications , Stroke/complications , Virus Activation , Animals , Brain/pathology , Brain/virology , DNA, Viral/analysis , DNA, Viral/blood , Encephalitis, Viral/pathology , Herpesvirus 1, Human/genetics , Herpesvirus 1, Human/isolation & purification , Intracranial Hemorrhages/pathology , Male , Mice , Stroke/pathologyABSTRACT
Effective influence of the drug Cerebral and its micro- and macrofractions on the mean lifespan and degenerative process dynamics of Drosophila melanogaster have been investigated. No dose--effect dependence was detected when different concentrations of Cerebral were used. The administration of Cerebral as a neuroactivating remedy combined with piracetam and verapamil was most effective, leading to an increase in the lifespan and a delay in the appearance of brain degenerative processes.
Subject(s)
Brain/drug effects , Drosophila melanogaster/physiology , Longevity/drug effects , Neurons/drug effects , Neuroprotective Agents/pharmacology , Peptides/pharmacology , Animals , Brain/pathology , Drosophila melanogaster/genetics , Mutation , Neurons/pathology , Piracetam/pharmacologyABSTRACT
Experimental studies were made of rat immunoreactivity in experimental modeling of acute hemorrhagic stroke in staphylococcal infection. Bactericidal activity and reserve bactericidal activity of neutrophils in NBT-test enhance while mid-molecular CIC level decreases because of phagocyte activation. ABA high titers in blood reflect activation of autoimmune processes. Splenic mass increased suggesting activation of proliferation of splenic lymphoid cells or enhanced migration of immature lymphoid cells from bone marrow to the spleen. Experimental animals had suppressed functional activity of main lymphoid cells populations in blast-transformation reaction which may affect the course of early recovery, promote activation of infectious bacterial process, autoaggression. The results of the studies can serve the basis for further investigations of immune mechanisms involved in development of hemorrhagic stroke in the presence of infectious process.
Subject(s)
Cell Proliferation , Lymphocyte Activation/immunology , Lymphocytes/immunology , Neutrophils/immunology , Staphylococcal Infections/immunology , Stroke/immunology , Animals , Bone Marrow Cells/immunology , Male , Rats , Spleen/immunology , Stroke/microbiologyABSTRACT
The study of an interferon-inducing action of neuropeptides (a cerebrolysin model) on production of interferons by human blood leukocytes has shown that neuropeptides induce gamma-interferon production in the titer 267 IU/ml that determines one of the mechanisms of a neuroimmunocorrecting effect of cerebrolysin (Ebewe, Austria) in many neurological diseases (acute stroke, brain traumas and different neuroinfectious diseases).
Subject(s)
Amino Acids/pharmacology , Interferon-gamma/biosynthesis , Leukocytes/metabolism , Neuropeptides/pharmacology , Neuroprotective Agents/pharmacology , Animals , Cells, Cultured , Humans , Leukocytes/cytology , SwineABSTRACT
Neuroimmunocorrection therapy with cerebrolysin has been used for the prophylaxis of clinical pneumonia development in the early stage of acute stroke in a group of 140 patients with heavy clinical course of acute ischemic stroke (AIS). All patients in the test and control groups received the basal anti-AIS therapy and antibacterial drugs (IV-generation cephalosporins) in case of pneumonia development. The efficacy of cerebrolysin administration was evaluated both on the clinical scale (NIH-NINDS, CPIS, SIRS immonograms) and using laboratory indices. It is established that the proposed neuroimmunocorrection therapy with cerebrolysin decreases the frequency of the clinical pneumonia development. A relationship between the pneumonia onset rate and the focus localization in limbico-diencephalic part of the brain is established. The use of cerebrolysin decreases lethality, normalizes the impaired immunity indices, accelerates the restoration of violated neural functions, suppresses pneumonia development, restores the level of albumin, and normalizes the laboratory indices of inflammatory syndrome.
Subject(s)
Amino Acids/therapeutic use , Anti-Bacterial Agents/therapeutic use , Cross Infection/prevention & control , Neuroimmunomodulation/drug effects , Neuroprotective Agents/therapeutic use , Pneumonia, Bacterial/prevention & control , Stroke , Aged , Amino Acids/administration & dosage , Anti-Bacterial Agents/administration & dosage , Cross Infection/blood , Cross Infection/immunology , Drug Therapy, Combination , Humans , Immunity, Innate/drug effects , Neuroprotective Agents/administration & dosage , Pneumonia, Bacterial/blood , Pneumonia, Bacterial/immunology , Serum Albumin , Stroke/blood , Stroke/complications , Stroke/immunology , Treatment OutcomeABSTRACT
We studied immunological and morphological changes in rat brain in an acute period of experimental hemorrhagic stroke (HS). The latter was induced mechanically by the method of A. N. Makarenko et al (the area of destruction in the rat brain was 0.15-0.2 mm3 in the internal capsule (c.i.) of both hemispheres) in 105 noninbred white male and female mice (body mass 18-22 g) and 20 Wistar rats (body mass 200-220 g). The rats were decapitated on day 1, 3, 10. HS modeling in mice is accompanied with immune disorders: high production of hemagglutinating antibodies in parallel with low titer of hemolysines, significant reduction of thymic mass and intensification of delayed type hypersensitivity. Besides changes typical for an acute period of HS, histological studies of the brain revealed encephalitic lesions located both near HS foci and far from them in 10 test animals of 14 on days 3-10. We observed signs of productive ependymitis and focal vasculitis (capillaritis). The infiltrates consisted primarily of microglyal cells and lymphocytes. In the controls such changes occurred in 1 of 6 rats. The results show that in an acute period of HS in rats their brain may be affected with activated latent infection and encephalitis. The same phenomenon may be observed in humans.
Subject(s)
Encephalitis/immunology , Encephalitis/pathology , Stroke/complications , Animals , Disease Models, Animal , Immunity , Mice , Rats , Rats, WistarABSTRACT
A scheme of complex administration of drugs in the order neuroprotector + neuroactivator + neuroretarder for the treatment of neurodegenerative processes in the brain has been elaborated and tested on a model object representing neurodegenerative mutants of Drosophila melanogaster. The appearance of changes in the brain was delayed when drugs were used separately: donepezil hydrochloride (arisept), 10 - 11 days, epinephrine and nimodipine, 1 - 2 days. The treatment of flies with the same drugs in the order arisept + epinephrine + nimodipine leads to the complete regeneration of D. melanogaster brain tissue to within 15 days of imago life.
Subject(s)
Calcium Channel Blockers/therapeutic use , Epinephrine/therapeutic use , Indans/therapeutic use , Neurodegenerative Diseases/drug therapy , Nimodipine/therapeutic use , Nootropic Agents/therapeutic use , Piperidines/therapeutic use , Animals , Disease Models, Animal , Donepezil , Drosophila melanogaster , Drug Therapy, Combination , Mutation , Neurodegenerative Diseases/geneticsABSTRACT
Active anti-stroke fraction of Cerebral preparation (extract of water-soluble molecules from brain tissue of animals with hemorrhagic stroke) decreased caspase-3 expression and improved survival of experimental animals in the acute period after hemorrhagic stroke.
Subject(s)
Amyloid beta-Protein Precursor/antagonists & inhibitors , Caspase Inhibitors , Cerebral Hemorrhage/drug therapy , Stroke/drug therapy , Tissue Extracts/therapeutic use , Acute Disease , Amyloid beta-Protein Precursor/genetics , Amyloid beta-Protein Precursor/metabolism , Animals , Caspase 3 , Caspases/genetics , Caspases/metabolism , Cerebral Hemorrhage/enzymology , Cerebral Hemorrhage/metabolism , Male , RNA, Messenger/analysis , RNA, Messenger/metabolism , Rats , Stroke/enzymology , Stroke/metabolism , Tissue Extracts/pharmacologyABSTRACT
The effect of the new drug "cerebral" and its fractions 1-3 on the model of bilateral hemorrhagic stroke in white rats was studied with reference to the action of cebrolysin and cerebrolysate-M. With respect to the general functional state, behavioral activity restoration, and morphological data, the most pronounced antistroke action was observed for the cerebral-1 fraction. This fraction was further separated into three subfractions. The most promising test results were obtained for the 1.2 subfraction, which was selected for the further investigation.
Subject(s)
Amino Acids/administration & dosage , Amino Acids/isolation & purification , Behavior, Animal/drug effects , Cerebral Hemorrhage/drug therapy , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/isolation & purification , Administration, Intranasal , Amino Acids/chemistry , Animals , Cerebral Hemorrhage/pathology , Male , Neuroprotective Agents/chemistry , Rats , Rats, WistarABSTRACT
The new drug cerebral, as well as its low-molecular-weight (LMW) fraction (MW, < or = 500 Da) separated from a ready-to-use commercial form of this new neutrotropic drug, increases the level of synthesis and secretion of the nerve growth factor (NGF) in rats under conditions of experimental hemorrhagic stroke (HS), while not influencing the NGF synthesis and secretion in intact animals. This neuroactivating effect of the trophinotropic drug cerebral and its LMW fraction in the acute HS development stage was observed upon intranasal administration. In comparison with parenteral (intraperitoneal) administration, the intranasal introduction provides for the optimum drug delivery to the CNS bypassing the blood-brain barrier. Trophinotropic agents are a new class of drugs with neuroactivating mechanism of action upon the NGF synthesis and secretion under HS conditions.
Subject(s)
Brain/drug effects , Cerebral Hemorrhage/metabolism , Nerve Growth Factors/metabolism , Neuroprotective Agents/pharmacology , Administration, Intranasal , Animals , Cerebral Hemorrhage/drug therapy , Cerebral Hemorrhage/genetics , Gene Expression/drug effects , Male , Molecular Weight , Nerve Growth Factors/genetics , Neuroprotective Agents/chemistry , Rats , Up-RegulationABSTRACT
A homogeneous low-molecular-weight fraction (MW, 350-500 Da) separated from a ready-to-use commercial form of the new neurotropic drug cerebral (for amino acid composition see Arkh. Psikh. 3(18), 138-143 (1998)) increases the survival of experimental rats upon experimental hemorrhagic stroke (HS). The distribution and accumulation of tritium-labeled preparation was studied in various tissues (tractus olfactorius, bulbus olfactorius, damaged neocortex region, hippocampus, hypothalamus, midbrain, pons, medulla oblongata, cerebrum, liver) and in the blood of intact, shame-operated (SO), and HS rats 20 and 120 min after intranasal administration. A significant amount of the labeled drug is accumulated for 20 min in all structures of the brain, liver, and blood. After 120 min, the level of accumulated drug proportionally increases. The amount of labeled preparation accumulated in SO and HS rats is greater than that in intact rats. The character of cerebral accumulation in tractus olfactorius and bulbus olfactorius upon intranasal administration is indicative of the effective drug transport to CNS via these pathways. Therefore, the intranasal administration can offer a promising means of clinical treatment of HS patients.
Subject(s)
Amino Acids/pharmacokinetics , Administration, Intranasal , Amino Acids/administration & dosage , Amino Acids/chemistry , Animals , Brain/metabolism , Cerebral Hemorrhage/blood , Cerebral Hemorrhage/metabolism , Chemical Fractionation , Liver/metabolism , Male , Rats , Tissue Distribution , TritiumABSTRACT
The effect of the new nootropic drug nooglutyl, a positive modulator of AMPA-subtype glutamatergic receptors, was studied in rats with a model hemorrhagic stroke (HS)--posttraumatic hematoma induced by cerebral tissue destruction in the capsule interna region. Single intraperitoneal injections of nooglutyl (10 and 20 mg/kg) 3-4 h after operation decreased the HS-induced neurological deficiency, restored the coordination of movements, improved the passive avoidance reaction retrieval, and prevented the loss of experimental animals. The results show evidence of a pronounced neuroprotector action of nooglutyl in rats with the HS model.
Subject(s)
Cerebral Hemorrhage, Traumatic/drug therapy , Glutamates/therapeutic use , Neuroprotective Agents/therapeutic use , Nicotinic Acids/therapeutic use , Animals , Brain/drug effects , Brain/physiopathology , Cerebral Hemorrhage, Traumatic/mortality , Cerebral Hemorrhage, Traumatic/physiopathology , Conditioning, Psychological/drug effects , Learning/drug effects , Male , Memory/drug effects , RatsABSTRACT
Data on the development of three experimental models of hemorrhagic stroke in mice are reported. The models differ in the extent of damage. From the standpoint of the immunopharmacological investigation, most adequate model is provided by the light acute brain circulation disorder (LABCD). In the LABCD model, the hemorrhagic stroke is characterized by reduction in the thymus weight, inhibition of the antibody (hemolysin) synthesis, and enhancement of the delayed type hypersensitivity response. The new antistroke drug cerebral decreased (especially after intranasal administration) the level of lethality in experimental animals and improved the immunological indices.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Cerebral Hemorrhage/immunology , Immune System/drug effects , Stroke/immunology , Animals , Antibody Formation/drug effects , Cerebral Hemorrhage/etiology , Female , Hypersensitivity, Delayed/drug therapy , Male , Mice , Stroke/complicationsABSTRACT
The antihypoxant and membranoprotector properties of the new intraorganoid pharmacological preparation mitochondrin (M-1) were studied in two series of experiments. In the first series, the drug activity was studied on a model of hypoxia with hypercapny; in the second series, the drug was tested on a model of hemic hypoxia caused by neurotoxic damage (acute nitrobenzene intoxication). It was established that M-1 (obtained from the brain tissue of newborn rabbits) possesses antihypoxant activity, which is manifested in both hypoxia--hypercapnia and hemic hypoxia. The drug effect was more pronounced 3 h after administration than on the next day. The antihypoxant action of M-1 is related to the cytomembrane neuroprotector activity.
Subject(s)
Hypoxia/drug therapy , Tissue Extracts/therapeutic use , Animals , Brain/ultrastructure , Erythrocytes/drug effects , Erythrocytes/metabolism , Hypoxia/blood , Hypoxia/chemically induced , Male , Mice , Mitochondria/chemistry , Nitrobenzenes , Osmotic Pressure , Rabbits , Rats , Tissue Extracts/isolation & purificationABSTRACT
A standardized experimental model of intracerebral hemorrhagic stroke in small laboratory animals is developed and advanced for chronic neurobiological studies of normal and pathological higher nervous activity as well as disorders developed after acute hemorrhages. A device is advanced which allows a researcher to destroy appropriate brain structures (tissues and local blood vessels) with necessary precision by four-six rotations of curved stereotaxically inserted mandrel-wire knife and, subsequently, to inject autoblood into the area of the lesion. The advanced model is convenient for the reproduction of lesions in different brain regions (for the purpose of experimental knockouts) in neurophysiological, neuropharmacological, and clinical investigations.
Subject(s)
Brain/surgery , Intracranial Hemorrhage, Hypertensive/etiology , Neurophysiology/methods , Animals , Disease Models, Animal , Intracranial Hemorrhage, Hypertensive/pathology , Neurophysiology/instrumentation , Rats , Stereotaxic Techniques/instrumentation , Surgical InstrumentsABSTRACT
Effect were studied of a dosed chest compression on the arterial pressure (AP) in stage I-II hypertensive disease. AP was recorded at all procedures, during the whole time the respective procedure was being conducted and during five days following the course of treatment. A significant hypotensive effect was recordable in the wake of chest compression.